医学
对数秩检验
比例危险模型
肺癌
TNM分期系统
危险系数
内科学
队列
回顾性队列研究
阶段(地层学)
肿瘤科
生存分析
癌症
放射科
肿瘤分期
古生物学
生物
置信区间
作者
In Ha Kim,Geun Dong Lee,Se Hoon Choi,Hyeong Ryul Kim,Yong Hee Kim,Dong Kwan Kim,Seung-Il Park,Jae Kwang Yun
标识
DOI:10.1016/j.jtho.2024.04.002
摘要
The aim of this study was to validate the discriminatory ability and clinical utility of the N descriptor of the newly proposed 9th edition of the TNM staging system for lung cancer in a large independent cohort.We retrospectively analyzed patients who underwent curative surgery for non-small cell lung cancer (NSCLC) between January 2004 and December 2019. The N descriptor of patients included in this study was retrospectively reclassified based on the 9th edition of the TNM classification. Survival analysis was performed using the log-rank test and Cox proportional hazard model to compare adjacent N categories.A total of 6649 patients were included in this study. The median follow-up period was 54 months. According to the newly proposed 9th edition N classification, 5573 (83.8%), 639 (9.6%), 268 (4.0%), and 169 (2.5%) patients were classified into the clinical N0, N1, N2a, and N2b categories and 4957 (74.6%), 744 (11.2%), 567 (8.5%), and 381 (5.7%) were classified into the pathologic N0, N1, N2a, and N2b categories, respectively. The prognostic differences between all adjacent clinical and pathologic N categories were highly significant in terms of both overall survival (OS) and recurrence-free survival (RFS).We validated the clinical utility of the newly proposed 9th edition N classification for both clinical and pathologic stages in NSCLC. The new N classification showed clear prognostic separation between all categories (N0, N1, N2a, and N2b) in terms of both OS and RFS.
科研通智能强力驱动
Strongly Powered by AbleSci AI